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AN ADAPTIVE BAYESIAN DESIGN FOR A RANDOMIZED TRIAL OF HIGH-
VERSUS LOW-LEVEL TACROLIMUS AS PROPHYLAXIS FOR GRAFT-VER-
SUS-HOST DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION
Thall, P.F., Wooten, L.H., Couriel, D.R., Champlin, R.E. The Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX.
We describe a Bayesian adaptive design for a randomized phase
II/III clinical trial to compare 2 different tacrolimus (FK506) blood
levels for the prevention of graft-versus-host disease (GVHD) after
allogeneic hematopoietic stem cell transplantation. The scientiﬁc
objectives are to estimate differences in overall survival, regimen-
related mortality, acute GVHD, and toxicity at high (8–12 ng/mL)
versus low (4–6 ng/mL) tacrolimus blood levels, and to estimate
the rates of these events within each treatment group. The trial is
currently ongoing at M.D. Anderson Cancer Center. The clinical
goal of the trial is to ﬁnd the lowest blood level of tacrolimus that
can give the highest amount of protection against GVHD with the
fewest side effects possible. The randomization scheme dynami-
cally balances the 2 arms with respect to patient age ( 45 v.  45
years) and source of cells (bone marrow vs peripheral blood). A
Bayesian probability model accounting for patient prognostic co-
variates (age and cell source) and the times to acute GVHD, disease
recurrence, and death from time of transplantation was used as a
basis for constructing multiple interim monitoring rules to termi-
nate either treatment arm for safety or stop the trial due to either
futility or superiority. The rules are applied continuously through-
out the trial, with either arm stopped early if the probability of
acute GVHD within 100 days or disease recurrence or death
within 180 days is unacceptably high. Additionally, the trial will be
stopped early if the posterior probability that one arm is superior
to the other in terms of their 180-day success rates exceeds 99.5%.
The computer code for randomization, probability calculations
(numerical integration) and simulation of the design is written in
the C programming language using the C numerical li-
brary developed by the software development team in the Depart-
ment of Biostatistics and Applied Mathematics at M.D. Anderson
Cancer Center. The trial is being conducted using a web-based
user interface with SQL server for data storage.
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DATA CONNECTION: WWW.DATAMANAGER.BLOGSPOT.COM. A CLIN-
ICAL RESEARCH PROFESSIONALS AND DATA MANAGER NETWORK
Laursen, H.B.1, Bellman, D.2, McCrae, J.3, Knutson, D.4,
Rogers, J.M.5, Manion, K.L.6 1Rigshospitalet, Copenhagen, Denmark;
2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 3Prin-
cess Margaret Hospital, Toronto, ON, Canada; 4CIBMTR, Milwaukee,
WI; 5CHLA, Los Angeles, CA; 6Emory Healthcare, Atlanta, GA.
Background. To minimize, mediate, and operate between clin-
ical research professionals (CRPs) and data managers (DMs posi-
tioned around the world and international registries such as the
CIBMTR (Center for International Blood and Marrow Transplant
Research), a CRP and DM network was founded in cooperation
with the CIBMTR. The aim of the network is to ensure that
individual BMT centers’ standard operating procedures (SOP)
meet the registries’ criteria in relation to documentation, data
collection, and fulﬁllment of international requirements. To fulﬁll
this aim, a website was launched in September 2003 including the
following internal websites: “Data Connection,” “News and Infor-
mation,” “Question and Answers,” “Mentors,” and “Helping Hand
Guide to Data Managers” and links to external websites. These
websites all address core information and communication between
CRP/DMs and the CIBMTR in relation to ﬁlling out different
forms, but do not address the aspects of the CRP and DM work
that cross between the different registries and institutions. The aim
of this study was to determine how we can help CRPs and DMs
organize the daily work. Methods. Gather information and expe-
riences from CRPs and DMs on how to solve these tasks and
publish it on internal websites so others can beneﬁt from their
experience. Results. Because CRPs and DMs face audits from
different registries, an audit website has been launched with expe-
riences, tips, and ideas that might be beneﬁcial when challenged
with an audit. The internal website “Organizing the Work” con-
veys tips and ideas on how to organize the daily work, gather the
information and source documentation required to meet the dif-
ferent registries as well as each institution’s SOP. The aim of the
“Meeting” website is to inform CRPs and DMs on upcoming
meetings and important events. “Notice Board” is a website that
gives CRPs and DMs an opportunity to place a notice or request.
Conclusions. The mentoring network is a new form of IT-based
cooperation and communication between CRPs, DMs, and the
CIBMTR. The aim of the network and Web site is to convey news
and information to provide a useful reference tool for CRPs and
DMs in their daily work and to provide CRPs and DMs with a
sense of belonging by ﬁlling the gap between the single BMT unit
and the national/international registry. To achieve this aim, the
network continues to need the support and the cooperation from
CRPs, DMs, and the CIBMTR.
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IMPACT OF INFECTIOUS COMPLICATIONS ON THE OUTCOME IN PA-
TIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
Rhee, J.-Y.1, Kim, S.T.2, Jang, E.H.1, Ki, H.K.1, Moon, C.-S.1,
Lee, S.H.2, Oh, W.S.1, Kim, K.H.2, Kim, W.S.2, Jung, C.W.2,
Peck, K.R.1, Song, J.-H.1 1Division of Infection, Department of Medi-
cine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea; 2Division of Hemato-oncology, Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School
of Medicine, Seoul, Korea.
Background. This study was conducted to investigate the affect
of infectious complications on outcome in patients with hemato-
poietic stem cell transplantation (HSCT). Methods. All patients
who underwent HSCT from February 1996 to October 2003 were
enrolled. Their medical records and microbiologic data were re-
viewed. Results: A total of 272 patients (136 allogenic, 133 autol-
ogous, and 3 cord HSCT) were enrolled (mean age, 37 years; mean
follow-up duration, 26 months). Acute myeologeneous leukemia
(27.5%) was the most common underlying disease, followed by
lymphoma (19.5%) and chronic myelogeneous leukemia (14.3%).
A total of 821 infectious episodes were observed in 247 patients.
Infectious complications occurred more commonly in allogeneic
recipients (3.57  2.81 episodes) than in autologous recipients
(2.62  2.42 episodes) (P  .003). Microbiologically documented
infection (MDI), clinically documented infection, and unknown
fever accounted for 39.4%, 35.8%, and 24.8% of these episodes,
respectively. Pneumonia (20.4%) was the most common infection,
followed by primary bacteremia (13.8%) and enterocolitis (13.6%).
Among 323 MDIs, bacterial infection, viral infection, and fungal
infection accounted for 52.6%, 41.4%, and 6.0%, respectively.
Escherichia coli (14.5%) was the most common bacterial isolate from
blood, followed by Klebsiella spp. (9.8%) and Pseudomonas spp.
(8.3%). Infectious complications developed most frequently in the
early posttransplantation period (41.5%), followed by the late pe-
riod (35.8%) and the intermediate period (22.7%). In the interme-
diate period, there were 52.2% (12/23) cases of CMV disease and
69.2% (45/65) cases of CMV infection. Relapse rate of the under-
lying disease was 29.4%. A total of 56 of the 74 deaths related to
infection occurred in the late posttransplantation period, and
82.1% of them were related to relapse of the underlying disease.
Bacteremia (P  .004), Gram-positive bacterial infections (P 
.028), Gram-negative bacterial infections (P  .043), fungemia
(P  .02), and fungal pneumonia (P  .029) were related to the
mortality. Conclusions. Infections contributed to 60.66% of total
mortality in patients with HSCT. In the late posttransplantation
period, high infection-attributable mortality rate was related
mainly to relapse of the underlying disease. A high rate of CMV
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infection in the intermediate period and deaths caused by multire-
sistant Gram-negative bacteria in the late period were revealed.
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CORE INFORMATION REPORTED TO DONOR CENTERS AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION (SCT)
Laursen, H.B., Lanther, T., Holder, J. Rigshospitalet, BMT Unit 4042,
Copenhagen, Denmark.
Background. The purpose of this study is to identify the follow-
ing topics: (1) what information regarding the recipient’s medical
history European Donor Centers (EDC) deﬁne as essential; (2)
frequency of recipient follow-up (FU) information to EDCs; and
(3) information ﬂow to the donor regarding the recipients medical
history posttransplantation. Methods. A questionnaire was faxed
to 38 EDCs. Of these, 21 (55.3%) responded. One of these 21
EDCs declined to answer, and another had delegated the FU
program to another national center, so the results are based on the
19 EDCs that completed the questionnaire. Results. Sixteen of the
19 EDCs (84.2%) had a recipient FU questionnaire. The following
analysis is based on the answers from the 16 EDCs with a FU
questionnaire.The frequency of FU information by days (D) post
SCT was D 30, 4 EDCs; D 60, 1 EDC; D 90, 6 EDCs; D 100, 3
EDCs; D 120, 2 EDCs; D 180, 8 EDCs; 1 year, 13 EDCs; yearly,
11 EDCs. Fourteen of the 16 (87.5%) EDCs with a FU program
used the same questionnaire for all FU requests, and 6 (37.5%) of
the 16 EDCs redesigned their FU questionnaire according to
research projects. The EDCs’ frequency of follow-up information
was based on national standards in 4 (25%), international standards
in 7 (43.8%), both national and international standards in 2
(12.5%), and other standards in 3 (18.8%).
The donor access to FU information regarding the recipients
condition was given as follows: no information given in 3 (17.8%),
information automatically given to the donor in 3 (18.8%), infor-
mation given on donor request in 8 (50%), information given by
the collection center in 1 (6.3%), and other in 1 (6.3%).
Changes in the patient’s condition are not reported to the donor
in 13 (81.2%), are reported to the donor in 1 (6.3%), and are
reported only on request from the donor in 5 (31.3%). The donor
is not informed if the patient dies in 8 (50%), the donor is informed
in 3 (18.8%), and the donor is informed only on request in 5
(31.3%).
Twelve EDCs gave information on the content of their FU
questionnaire. The most frequent questions asked are regarding
date of transplantation and survival status in 12 (100%); date and
cause of death, Lansky/Karnofsky score in 11 (91.7%); AGvHD,
recurrence or relapse of disease in 10 (83.3%); engraftment, re-
transplantation/DCI in 9 (75%); and chronic GvHD in 8 (66.7%).
Conclusions. Because only 55.3% of the EDCs participated in
this study. the results should be interpreted with caution. Most
EDCs have a recipient FU program, but there is no agreement
among EDC on dates of the FU information and by what standards
this information should be provided. Some 82% of the EDCs
provide information to the donor regarding the recipient’s condi-
tion.
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HEMATOPOIETIC CELL TRANSPLANTATION (HCT) INFORMATION CEN-
TER: A DATA MANAGEMENT SYSTEM AND A GATEWAY TO STANDARD
STATISTICS
Saracino, G.1, Pineiro, L.2, Berryman, B.R.2, Fay, J.W.2, Vance, E.A.2,
Woelfel, R.G.1, Balderas, M.2, Agura, E.D.2 1Baylor University Med-
ical Center, Dallas, TX; 2Baylor Sammons Cancer Center and Texas
Oncology, P.A., Dallas, TX.
Background. Efﬁcient data collection and management of HCT
clinical data are essential in reporting patient transplantation out-
come and clinical research. Collection of this data in real time with
frequent updates requiring daily communication between data
managers, clinical investigators and afﬁliated staff is challenging,
especially in a large hematopoietic cell transplantation program.
Such an approach, however, minimizes the incidence of missing
data and facilitates a complete and accurate transplantation data-
base. Thus, transplantation data collected in this fashion should
result in high-quality data for cooperative transplantation regis-
tries, manuscript submission, and ﬁnancial staff. The aims of this
study were to provide a user-friendly interface to standardized
transplantation outcome statistics, and to provide access to various
data management applications to authorized users within the trans-
plantation program provided by a HCT Information Center at
Baylor University Medical Center (BUMC). Method. The HCT
Information Center at BUMC has been established to provide a
web-based interface for reporting, statistical analysis, and online
forms. The system includes SAS macros developed to process
data from Oracle and Microsoft Access databases and to create
customized reports, standard statistics,and SAS ActiveX graphs
updated automatically. The system provides different levels of
access to different groups of authorized users. Results. The pro-
cesses of data management, quality assurance monitoring, and data
validation have been supported by customized reports and tracking
tools (eg, last contact/follow-up, missing data, error reporting).
Physicians, clinical investigators, and authorized users have access
to valid up-to-date statistical information regarding patients/do-
nors undergoing blood and marrow transplantation. Examples of
available analysis include disease-related outcome statistics, such as
Kaplan-Mayer survival curves, and analysis of infection control
data, such as trends in antibiotic resistance patterns. Conclusions.
The HCT Information Center provides users with beneﬁcial and
accurate information that allows tracking of patients’ progress
during and after transplantation as well as long-term outcomes. It
allows us to compare our center’s outcomes with those published
by CIBMTR. Most important, it helps us ensure better quality and
completeness of the data collected for publication and submission
to transplantation reporting agencies.
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